Aardvark Therapeutics, Inc. (AARD) Discusses Efficacy and Safety Data From Terminated HERO Phase III and Open-Label Extension Trials Transcript
Aardvark Therapeutics is currently in a high-stakes transition toward Phase III clinical execution, characterized by a rapid escalation in R&D spending that has reached $16.6 million per quarter as of 2026Q1.
Price trend, volume and key moving averages
Trailing total returns as of 11/9/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 11, 2026 | -$0.66+24.5% vs -$0.87 | — vs — |
Q2 2026 May 7, 2026 | -$0.99-12.9% vs -$0.88 | — vs — |
Q2 2026 Mar 23, 2026 | -$0.81+2.1% vs -$0.83 | — vs — |
Q4 2025 Nov 13, 2025 | -$0.75+6.1% vs -$0.80 | — vs — |
Aardvark Therapeutics, Inc. (AARD) Discusses Efficacy and Safety Data From Terminated HERO Phase III and Open-Label Extension Trials Transcript
Aardvark Therapeutics Inc. (NASDAQ:AARD) stock plunged on Friday after the release of exploratory efficacy data from its terminated Phase 3 HERO trial and open-label extension study.
SAN DIEGO, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark or the Company) (Nasdaq: AARD), a clinical-stage biopharmaceutical company developing novel, small-molecule therapeutics designed to suppress hunger for the treatment of Prader-Willi syndrome (PWS) and metabolic diseases, today reported exploratory efficacy data from its previously terminated Phase 3 Hunger Elimination or Reduction Objective (HERO) trial and open-label extension (OLE) trial. As previously announced, Aardvark unblinded the data accumulated across both the HERO trial and OLE trial to assess the totality of available efficacy and safety data to inform the path forward for ARD-101.
Clinical development of ARD-101 for hyperphagia in Prader-Willi Syndrome (PWS) may resume Aardvark will host a webcast to review available dataset from the terminated Phase 3 HERO trial and OLE trial on Friday, October 23, 2026, at 8:00 a.m. EST SAN DIEGO, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark or the Company) (Nasdaq: AARD), a clinical-stage biopharmaceutical company developing novel, small-molecule therapeutics designed to suppress hunger for the treatment of Prader-Willi Syndrome (PWS) and metabolic diseases, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Company's Investigational New Drug application for ARD-101 for the treatment of hyperphagia in PWS.
Benchmark AARD against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Aardvark Therapeutics, Inc. Common Stock (AARD)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.17 | $25.6M | -0.37 | — | — | -71.54% | — | |
| $112.28 | $7.7B | -40.00 | 45.83% | -69.03% | -83.68% | — | |
| $3.82 | $229.72M | -0.84 | 8.72% | -119.87% | -106.94% | — | |
| $30.53 | $6.3B | -11.66 | — | -7585.86% | -69.59% | — | |
| $11.31 | $695.09M | -3.40 | — | — | -52.89% | — | |
| $26.84 | $3.13B | -5.05 | — | — | -117.35% | — |
Aardvark Therapeutics, Inc. Common Stock (AARD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Aardvark Therapeutics, Inc. Common Stock (AARD) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 17, 2026·SEC
Aug 11, 2026·SEC
Jun 12, 2026·SEC
Get notified when AARD posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Aardvark Therapeutics, Inc. Common Stock (AARD) stock FAQ — growth, dividends, profitability & financials explained
No. Aardvark Therapeutics, Inc. Common Stock (AARD) reported a net loss of $69.9M over the trailing twelve months.
Aardvark Therapeutics, Inc. Common Stock (AARD) had a return on equity (ROE) of -71.5% over the trailing twelve months. A negative ROE means the company lost money over the period.
Aardvark Therapeutics, Inc. Common Stock (AARD) had negative free cash flow of $69.4M over the trailing twelve months.